Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis to offer not-for-profit medicines to treat Covid-19 patients
Novartis has said that it will provide medicines to governments, NGOs and other institutional customers in up to 79 eligible nations until a vaccine or curative treatment is
Novartis has said that it will provide medicines to governments, NGOs and other institutional customers in up to 79 eligible nations until a vaccine or curative treatment is
The deal includes an exclusive license for the intellectual property related to the FIT antibody-interferon fusion technology drug delivery platform originally developed by scientists at UCLA. The license
MGTA-456 is a cell therapy designed to provide a high dose of hematopoietic stem cells that are well-matched to the patient. The Company plans to enroll 12 patients
The deal combines Daiichi Sankyo’s ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX), building on a previous 2017 option agreement. Under the terms of the
Since 2015, scientists from Lilly and Dana-Farber have been working together on pre-clinical and clinical studies, molecular analyses of patient samples and the design and conduct of clinical
The company has announced the positive top-line safety and efficacy results from the MAP US study, which showed superiority of RHB-104 over placebo. RHB-104 is a proprietary and
The recommendation is based on the progression-free survival (PFS) and overall survival (OS) primary endpoints of the Phase III PACIFIC trial, and post-hoc subgroup analyses by PD-L1 expression
It is the fourth Sandoz biosimilar approved in Europe in past 18 months, and seventh in total. Hyrimoz is an inhibitor of tumor necrosis factor (TNF), a protein
Clinically relevant levels were reached after the first injection of PERSERIS without use of a loading dose or any supplemental oral risperidone.1 “Treatment adherence is a major challenge
The pharmaceutical secondary packaging company said that patients can handle their medication intake more easily owing to intelligent, interactive pharmaceutical packaging with integrated electronics. Faller said that its